Studies on Phytochemical constituents, Functional Group Identification and Antimicrobial Activity of Solanum nigrum (Solanaceae)

Phytochemical constituents, functional group identification and antimicrobial activity of ethanolic extract of Solanum nigrum were investigated. The phytochemical screening of the crude extract revealed the presence of alkaloids, reducing sugars, tannis, flavonoids, Phlobatannis, and steriods. The extract were subjected for identification of functional groups using infra red spectrophotometer, presence of C=O, C-H, C=C and CO were identified, these bonding structures are responsible for presence of alkyl groups, methyl groups, alcohols, ethers, esters, carboxylic acid and anhydrides. And the crude ethanolic extract of Solanum nigrum were assayed for in vitro antimicrobial activity against gram positive and gram negative bacteria and they were also subjected for antifungal activity and the zone of inhibition were compared with control drug Penicillin and Nystatin. Staphylococcus aureus as the most sensitive strains exhibited maximum zone of inhibition about 25.7mm among gram positive organism tested. Escherichia coli exhibits 30.1mm zone than that of standard penicillin positive control. Trichophyton mentagrophytes exhibits maximum zone of inhibition of about 26.1mm among the tested fungal species

PRODUCTION OF AMYLASE FROM CUCUMIS MELO USING ASPERGILLUS NIGER BY LIQUID FERMENTATION

Submerged fermentation was carried out using muskmelon shell as a substrate for the production of amylase using Aspergillus niger. It was observed that the activity started to peak at 60 hrs as 102.6 µg/ml/min, reached maximum at 118.56µg/ml/min at the 84th hrs and then went on decreasing at 108 hrs to111.72 µg/ml/min, respectively. The results show that the amylase activity was decreasing after the 3rd day of incubation in the same optimal conditions. The optimum temperature maintained for amylase activity, was 30°C at pH 8.The process parameters influencing the production of α-amylase were optimized. Key words: Cucumis melo, Aspergillus niger, α-Amylase, Submerged Fermentatio

Identification of Phytochemical Constituents of Aegle marmelos Responsible for Antimicrobial Activity against Selected Pathogenic Organisms

Antimicrobial activity and phytochemical constituents of an ethanolic extract of Aegle marmelos were investigated. The phytochemical screening of the crude extract revealed the presence of Alkaloids, Cardiac glycosides, Terpenoids, Saponins, Tannis, Flavonoids, and Steroids. The crude ethanolic extract was tested for antimicrobial activity against gram positive organisms of Bacillus subtilis (NCIM: 3471), Staphylococcus aureus (NCIM: 2079), gram negative Escherichia coli (NCIM: 2065) and Pseudomonas aeruginosa (NCIM: 2200) at different concentrations levels of 0.5, 1.0, 1.5, 2.0 and 2.5 mg/ml. At the 2.5 mg/ml concentration, gram negative Escherichia coli exhibits a zone of inhibition about 25.7mm; Pseudomonas aeruginosa 19.9mm; gram positive Staphylococcus aureus 29.0 mm; and Bacillus subtilis, a maximum zone of inhibition about 28.1 mm as compared to the control drug penicillin. Escherichia coli, Pseudomonas aeruginosa and Bacillus subtilis exhibit a maximum zone of inhibition, hence they were considered as susceptible to the plant extracts but Staphylococcus aureus doesn’t exhibit such a zone of inhibition and is therefore considered as resistant

Antimicrobial Activity of Aegle marmelos Against Pathogenic Organism Compared with Control Drug

The aqueous and ethanolic extracts from the leaves of Aegle marmelos traditionally used in Indian system of Medicines were screened against Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus and Bacillus subtilis by using disc diffusion test technique. Bacillus subtilis exhibit about 22mm inhibition zone were considered resistant. The zone of inhibition of the extract was compared with the standard antibiotics such as Penicillin. The study suggests that the plant is promising development of phytomedicine for antimicrobial properties

IgA Anti-β2-Glycoprotein I Autoantibodies Are Associated with an Increased Risk of Thromboembolic Events in Patients with Systemic Lupus Erythematosus

The clinical utility of testing for antiphospholipid antibodies (aPL) of IgA isotype remains controversial.To address this issue, we reasoned that if IgA aPL contribute to the clinical manifestations of the antiphospholipid syndrome, then an association with thromboembolic events should manifest in patients whose only aPL is of IgA isotype. We performed a retrospective chart review of 56 patients (31 with systemic lupus erythematosus [SLE] and 25 without SLE) whose only positive aPL was IgA anti-beta2-glycoprotein I (isolated IgA anti-beta2GPI) and compared their clinical features with 56 individually matched control patients without any aPL. Patients with isolated IgA anti-beta2GPI had a significantly increased number of thromboembolic events, as compared to controls. When patients were stratified into those with and without SLE, the association between isolated IgA anti-beta2GPI and thromboembolic events persisted for patients with SLE, but was lost for those without SLE. Titers of IgA anti-beta2GPI were significantly higher in SLE patients who suffered a thromboembolic event. Among patients with isolated IgA anti-beta2GPI, there was an increased prevalence of diseases or morbidities involving organs of mucosal immunity (i.e., gastrointestinal system, pulmonary system, and skin).The presence of isolated IgA anti-beta2GPI is associated with an increased risk of thromboembolic events, especially among patients with SLE. IgA anti-beta2GPI is associated with an increased prevalence of morbidities involving organs of mucosal immunity

Congenital hypothyroidism

Congenital hypothyroidism (CH) occurs in approximately 1:2,000 to 1:4,000 newborns. The clinical manifestations are often subtle or not present at birth. This likely is due to trans-placental passage of some maternal thyroid hormone, while many infants have some thyroid production of their own. Common symptoms include decreased activity and increased sleep, feeding difficulty, constipation, and prolonged jaundice. On examination, common signs include myxedematous facies, large fontanels, macroglossia, a distended abdomen with umbilical hernia, and hypotonia. CH is classified into permanent and transient forms, which in turn can be divided into primary, secondary, or peripheral etiologies. Thyroid dysgenesis accounts for 85% of permanent, primary CH, while inborn errors of thyroid hormone biosynthesis (dyshormonogeneses) account for 10-15% of cases. Secondary or central CH may occur with isolated TSH deficiency, but more commonly it is associated with congenital hypopitiutarism. Transient CH most commonly occurs in preterm infants born in areas of endemic iodine deficiency. In countries with newborn screening programs in place, infants with CH are diagnosed after detection by screening tests. The diagnosis should be confirmed by finding an elevated serum TSH and low T4 or free T4 level. Other diagnostic tests, such as thyroid radionuclide uptake and scan, thyroid sonography, or serum thyroglobulin determination may help pinpoint the underlying etiology, although treatment may be started without these tests. Levothyroxine is the treatment of choice; the recommended starting dose is 10 to 15 mcg/kg/day. The immediate goals of treatment are to rapidly raise the serum T4 above 130 nmol/L (10 ug/dL) and normalize serum TSH levels. Frequent laboratory monitoring in infancy is essential to ensure optimal neurocognitive outcome. Serum TSH and free T4 should be measured every 1-2 months in the first 6 months of life and every 3-4 months thereafter. In general, the prognosis of infants detected by screening and started on treatment early is excellent, with IQs similar to sibling or classmate controls. Studies show that a lower neurocognitive outcome may occur in those infants started at a later age (> 30 days of age), on lower l-thyroxine doses than currently recommended, and in those infants with more severe hypothyroidism

HE-LHC: The High-Energy Large Hadron Collider – Future Circular Collider Conceptual Design Report Volume 4

In response to the 2013 Update of the European Strategy for Particle Physics (EPPSU), the Future Circular Collider (FCC) study was launched as a world-wide international collaboration hosted by CERN. The FCC study covered an energy-frontier hadron collider (FCC-hh), a highest-luminosity high-energy lepton collider (FCC-ee), the corresponding 100 km tunnel infrastructure, as well as the physics opportunities of these two colliders, and a high-energy LHC, based on FCC-hh technology. This document constitutes the third volume of the FCC Conceptual Design Report, devoted to the hadron collider FCC-hh. It summarizes the FCC-hh physics discovery opportunities, presents the FCC-hh accelerator design, performance reach, and staged operation plan, discusses the underlying technologies, the civil engineering and technical infrastructure, and also sketches a possible implementation. Combining ingredients from the Large Hadron Collider (LHC), the high-luminosity LHC upgrade and adding novel technologies and approaches, the FCC-hh design aims at significantly extending the energy frontier to 100 TeV. Its unprecedented centre-of-mass collision energy will make the FCC-hh a unique instrument to explore physics beyond the Standard Model, offering great direct sensitivity to new physics and discoveries